WO2015092810A2 - Forme amorphe d'idélalisib - Google Patents

Forme amorphe d'idélalisib Download PDF

Info

Publication number
WO2015092810A2
WO2015092810A2 PCT/IN2014/000724 IN2014000724W WO2015092810A2 WO 2015092810 A2 WO2015092810 A2 WO 2015092810A2 IN 2014000724 W IN2014000724 W IN 2014000724W WO 2015092810 A2 WO2015092810 A2 WO 2015092810A2
Authority
WO
WIPO (PCT)
Prior art keywords
idelalisib
less
pharmaceutically acceptable
amorphous
solid dispersion
Prior art date
Application number
PCT/IN2014/000724
Other languages
English (en)
Other versions
WO2015092810A3 (fr
Inventor
Shriprakash Dhar DWIVEDI
Brij Khera
Kumar Kamlesh SINGH
Nikhil Amar SINGH
Original Assignee
Cadila Healthcare Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cadila Healthcare Limited filed Critical Cadila Healthcare Limited
Publication of WO2015092810A2 publication Critical patent/WO2015092810A2/fr
Publication of WO2015092810A3 publication Critical patent/WO2015092810A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)

Abstract

La présente invention concerne une forme amorphe d'idélalisib et des procédés pour la préparation de ladite forme amorphe. L'invention concerne également des compositions pharmaceutiques qui contiennent ladite forme amorphe d'idélalisib.
PCT/IN2014/000724 2013-11-20 2014-11-19 Forme amorphe d'idélalisib WO2015092810A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN3641/MUM/2013 2013-11-20
IN3641MU2013 IN2013MU03641A (fr) 2013-11-20 2014-11-19

Publications (2)

Publication Number Publication Date
WO2015092810A2 true WO2015092810A2 (fr) 2015-06-25
WO2015092810A3 WO2015092810A3 (fr) 2015-08-13

Family

ID=52785145

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IN2014/000724 WO2015092810A2 (fr) 2013-11-20 2014-11-19 Forme amorphe d'idélalisib

Country Status (2)

Country Link
IN (1) IN2013MU03641A (fr)
WO (1) WO2015092810A2 (fr)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016097314A1 (fr) * 2014-12-19 2016-06-23 Sandoz Ag Formes amorphes et cristallines d'idélalisib et procédé pour les produire
WO2016147206A1 (fr) 2015-03-13 2016-09-22 Mylan Laboratories Limited Procédé pour la préparation d'idélalisib amorphe et son mélange préliminaire
WO2016157136A1 (fr) 2015-04-02 2016-10-06 Mylan Laboratories Ltd Formes cristallines de l'idélalisib
WO2016165618A1 (fr) * 2015-04-15 2016-10-20 上海方楠生物科技有限公司 Substance amorphe d'idélalisibe et procédé de préparation associé
WO2017137097A1 (fr) * 2016-02-12 2017-08-17 Synthon B.V. Composition pharmaceutique comprenant de l'idelalisib sous forme amorphe
WO2017175184A1 (fr) * 2016-04-07 2017-10-12 Laurus Labs Limited Procédé de préparation de la forme amorphe d'idélalisib
EP3272348A1 (fr) 2016-07-21 2018-01-24 LEK Pharmaceuticals d.d. Composition pharmaceutique comportant de l'idelalisib
WO2019178596A1 (fr) 2018-03-16 2019-09-19 Johnson Matthey Public Limited Company Formes à l'état solide solvatées de pyridine ou de n,n-diméthylacétamide d'idélalisib solvaté, leur utilisation et leur préparation

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005113556A1 (fr) 2004-05-13 2005-12-01 Icos Corporation Quinazolinones utilisees en tant qu'inhibiteurs de la phosphatidylinositol 3-kinase delta humaine
WO2013134288A1 (fr) 2012-03-05 2013-09-12 Gilead Calistoga Llc Formes polymorphes de l'acide -2-(1-(9h-purine-6-ylamino)propyl)-5-fluoro-3-phénylquinazolin-4(3h)-one

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005113556A1 (fr) 2004-05-13 2005-12-01 Icos Corporation Quinazolinones utilisees en tant qu'inhibiteurs de la phosphatidylinositol 3-kinase delta humaine
WO2013134288A1 (fr) 2012-03-05 2013-09-12 Gilead Calistoga Llc Formes polymorphes de l'acide -2-(1-(9h-purine-6-ylamino)propyl)-5-fluoro-3-phénylquinazolin-4(3h)-one

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016097314A1 (fr) * 2014-12-19 2016-06-23 Sandoz Ag Formes amorphes et cristallines d'idélalisib et procédé pour les produire
WO2016147206A1 (fr) 2015-03-13 2016-09-22 Mylan Laboratories Limited Procédé pour la préparation d'idélalisib amorphe et son mélange préliminaire
US20180064714A1 (en) * 2015-03-13 2018-03-08 Mylan Laboratories Ltd Process for the Preparation of Amorphous Idelalisib and its Premix
WO2016157136A1 (fr) 2015-04-02 2016-10-06 Mylan Laboratories Ltd Formes cristallines de l'idélalisib
WO2016165618A1 (fr) * 2015-04-15 2016-10-20 上海方楠生物科技有限公司 Substance amorphe d'idélalisibe et procédé de préparation associé
US10370376B2 (en) 2015-04-15 2019-08-06 Alnova Pharmaceuticals, Ltd. Amorphous substance of Idelalisib and preparation method therefor
WO2017137097A1 (fr) * 2016-02-12 2017-08-17 Synthon B.V. Composition pharmaceutique comprenant de l'idelalisib sous forme amorphe
WO2017175184A1 (fr) * 2016-04-07 2017-10-12 Laurus Labs Limited Procédé de préparation de la forme amorphe d'idélalisib
EP3272348A1 (fr) 2016-07-21 2018-01-24 LEK Pharmaceuticals d.d. Composition pharmaceutique comportant de l'idelalisib
WO2019178596A1 (fr) 2018-03-16 2019-09-19 Johnson Matthey Public Limited Company Formes à l'état solide solvatées de pyridine ou de n,n-diméthylacétamide d'idélalisib solvaté, leur utilisation et leur préparation
US11358966B2 (en) 2018-03-16 2022-06-14 Johnson Matthey Public Limited Company Pyridine or N,N-dimethyl acetamide solvated solid state forms of solvated idelalisib, their use and preparation

Also Published As

Publication number Publication date
IN2013MU03641A (fr) 2015-07-31
WO2015092810A3 (fr) 2015-08-13

Similar Documents

Publication Publication Date Title
WO2015092810A2 (fr) Forme amorphe d'idélalisib
KR101251726B1 (ko) 닐로티닙 ＨＣｌ 결정형
US11292793B2 (en) Solid dispersions of amorphous Lumateperone p-Tosylate
WO2015044963A1 (fr) Vortioxétine amorphe et sels de ladite substance
US20140057925A1 (en) Amorphous form of vilazodone hydrochloride and process for its preparation
US20150018386A1 (en) Amorphous form of apixaban, process of preparation and compositions thereof
JP2011513497A (ja) レナリドミドの調製
WO2016038532A1 (fr) Tréprostinil diéthanolamine amorphe
WO2015139591A1 (fr) Forme cristalline du sel de sodium du dolutégravir et procédé pour sa préparation
CA2599415C (fr) Candesartan cilexetil micronise, stable et ses procedes de preparation
US20060111417A1 (en) Amorphous telmisartan
US20190300483A1 (en) POLYMORPHS OF BETRlXABAN & ITS MALEATE SALT
EP2825539A1 (fr) Forme amorphe de linagliptine et son procédé de préparation
US20150307540A1 (en) Amorphous form of dapagliflozin 1,2-propanediol
KR102276281B1 (ko) 의약으로 사용하기 위한 펄린돌 광학이성질체의 약학적으로 허용가능한 염
EP2872513A1 (fr) Formes cristallines d'un inhibiteur du vhc
KR102081071B1 (ko) 안정화된 무정형의 아고멜라틴, 이의 제조 방법 및 이를 함유하는 약제 조성물
WO2016193994A1 (fr) Selexipag amorphe et son procédé de préparation
US20190365738A1 (en) Amorphous solid dispersion of valbenazine tosylate and process for preparation thereof
WO2015114657A2 (fr) Forme amorphe de la base libre de la sitagliptine
KR20210089210A (ko) 실질적 비정질인 메조포러스 탄산마그네슘을 포함하는 신규한 비정질 활성 제약 성분
WO2019007317A1 (fr) Composition pharmaceutique et sa méthode de préparation
WO2017130219A1 (fr) Dispersion solide amorphe de palbociclib
Boukhris et al. NOVEL ORAL FORMULATION OF CYCLOSPORINE-SPRAY-DRIED DISPERSION USING CYCLODEXTRIN COPOLYMERS.
WO2013169523A1 (fr) Compositions à solubilité augmentée

Legal Events

Date Code Title Description
NENP Non-entry into the national phase in:

Ref country code: DE

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 14851422

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 14851422

Country of ref document: EP

Kind code of ref document: A2